Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer (Q27852078)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer	scientific article

Statements

scholarly article

1 reference

13 November 2016

Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer (English)

1 reference

13 November 2016

0 references

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

author name string

Ganapati V Hegde

1

0 references

Cecile C de la Cruz

2

0 references

Cecilia Chiu

3

0 references

Navneet Alag

4

0 references

Gabriele Schaefer

5

0 references

Lisa Crocker

6

0 references

Sarajane Ross

7

0 references

David Goldenberg

8

0 references

Mark Merchant

9

0 references

Janet Tien

10

0 references

Lily Shao

11

0 references

Leslie Roth

12

0 references

Siao-Ping Tsai

13

0 references

Scott Stawicki

14

0 references

Zhaoyu Jin

15

0 references

Shelby K Wyatt

16

0 references

Richard A D Carano

17

0 references

Yanyan Zheng

18

0 references

E Alejandro Sweet-Cordero

19

0 references

Yan Wu

20

0 references

Erica L Jackson

21

0 references

language of work or name

0 references

publication date

6 February 2013

0 references

Science Translational Medicine

0 references

5

0 references

171

0 references

171ra18

0 references

Characterization of clonogenic multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004438

20 April 2017

Somatic mutations affect key pathways in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004438

20 April 2017

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004438

20 April 2017

Identification of heregulin, a specific activator of p185erbB2

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004438

20 April 2017

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004438

20 April 2017

Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004438

20 April 2017

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3004438

20 April 2017

Tumour stem cells and drug resistance

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

20 April 2017

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

20 April 2017

The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

20 April 2017

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

20 April 2017

Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Residual tumor cells that drive disease relapse after chemotherapy do not have enhanced tumor initiating capacity

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Neuregulin-1 and human epidermal growth factor receptors 2 and 3 play a role in human lung development in vitro.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Neuregulin 1 in neural development, synaptic plasticity and schizophrenia

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Development of an autocrine neuregulin signaling loop with malignant transformation of human breast epithelial cells

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Biochemical analysis of the ligand for the neu oncogenic receptor

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004438

21 January 2018

Identifiers

10.1126/SCITRANSLMED.3004438

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27852078&oldid=1514750637"